Established brands, new products, networking of operations and improved efficiency in supply chain management have also helped the sales growth.
GR has restructured its product mix following its acquisition by Zydus Cadila. Zydus has shifted its anti-cancer drugs Oncotam and Mexate to GR.
GR and Zydus Cadila do not have much overlapping of products. Zydus is consolidating GRs product profile. It may transfer more drugs based on disease profile.
GRs operating profit rose 10.4 per cent to Rs eight crore. Margins fell a fraction from 17 per cent to 16.3 per cent owing to higher manufacturing expenses.
During the quarter, tax provision increased from Rs 1.4 crore to Rs 2.3 crore. Consequently, net profit declined 1.5 per cent to Rs four crore.
The company recently launched Actilyse for acute Ischaemic stroke.
The drug has the potential to dissolve the blood clot and restore the blood supply to the brain. A new Respicare division has been launched from April 2002.
This division will focus on specialised respiratory products and is expected to contribute significantly to the companys business in 2002-2003.
During the current fiscal, the company is likely to launch 12 new products including dry powder metered dose inhaler. These products may face tough competition from Cipla, Glaxo and a number of new entrants in the Rs 400 crore strong respiratory segment.
GR has major presence in a growing segment like womens healthcare and oncology.
Female healthcare accounts for a third of GRs total turnover. Foetus protection, menstrual postponement, female fertility hormones and female oral contraception are the main therapeutic groups covered under female healthcare.
The company also has presence in gastroenterology, diagnostics, pain management, infection, cough and cold, anti-spasm, hair loss, CNS (central nerves system), dermatology and nutrition.